[AI]Takeda signs US$600M AI drug discovery deal with Insilico

ChatGPT · July 3

Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japanese pharmaceutical company’s therapeutic areas.

The companies did not disclose which therapeutic areas or disease targets will be covered under the collaboration. The agreement gives Takeda access to Insilico’s Pharma.AI platform, which supports biological target identification, molecular design, and clinical trial prediction.

The companies said the collaboration will focus on identifying drug candidates that meet predefined scientific and early development criteria. Insilico will lead the AI-driven discovery work, while Takeda will take responsibility for advancing selected candidates through clinical development.

Deal value and development rights

Takeda will receive exclusive worldwide rights to develop, manufacture, and commercialise novel therapeutics selected through the collaboration.

Insilico said the deal includes about US$60 million in project initiation fees, near-term payments, and milestones. The total value could reach about US$600 million if preclinical, clinical, commercial, and sales milestones are achieved.

Additional payments are tied to preclinical, clinical, commercial, and sales milestones. Insilico is also eligible to receive tiered royalties on future sales.

Insilico founder and CEO Alex Zhavoronkov said proceeds from the deal will support early-stage research and development under the collaboration program. Zhavoronkov also said later-stage timelines will depend on Takeda’s clinical development activities and the coordinated work of both companies.

AI drug discovery partnerships

The Pharma.AI suite includes tools used for target discovery, molecule generation, and clinical development prediction. Published descriptions of the platform identify PandaOmics for target discovery, Chemistry42 for de novo small-molecule generation, and InClinico for forecasting clinical trial transition probability.

Insilico has also advanced its own AI-generated drug candidate into clinical testing. Rentosertib, formerly known as ISM001-055 or INS018_055, is a small-molecule TNIK inhibitor for idiopathic pulmonary fibrosis that was evaluated in a Phase 2a randomised clinical trial.

Chris Arendt, chief scientific officer and head of research at Takeda, said the agreement combines Takeda’s disease biology work with Insilico’s AI-enabled discovery capabilities. He said Takeda is also integrating automation, robotics, and generative AI into its discovery work.

The Insilico agreement follows another AI drug-discovery deal by Takeda earlier this year. In February, Takeda entered a multi-year collaboration with Iambic worth more than US$1.7 billion to use AI in the design of small-molecule drugs for ******* and gastrointestinal diseases.

Iambic’s platform includes NeuralPLexer, an AI model used to predict how drug molecules bind to proteins.

******** drugmakers signed 157 out-licensing deals worth US$135.7 billion in 2025, according to data cited by the South China Morning Post from China’s National Medical Products Administration.

In the Takeda–Insilico agreement, Takeda receives exclusive worldwide rights to candidates discovered through Insilico’s platform. Insilico said it has signed collaboration agreements with a combined potential value of more than US$7 billion since the start of the year.

Last month, Insilico announced a collaboration with South Korea’s SK Biopharmaceuticals focused on neuroimmune disorders. That agreement includes up to US$18 million in upfront and near-term milestone payments, with a total potential value of more than US$2.5 billion.

In March, Eli Lilly expanded its collaboration with Insilico in an AI-powered drug discovery deal worth up to US$2.75 billion. The agreement gave Lilly exclusive worldwide rights to develop, manufacture, and commercialise certain oral treatments then in preclinical development.

Insilico’s Hong Kong-listed shares rose 13.5% after the Takeda agreement was announced.

(Photo by

This is the hidden content, please

Sign In

or

Sign Up

)

See also:

This is the hidden content, please

Sign In

or

Sign Up